Palladino C.,University of Lisbon |
Palladino C.,Hospital General Universitario Gregorio Maranon |
Gomez M.L.N.,Hospital General Universitario Gregorio Maranon |
Soler-Palacin P.,Autonomous University of Barcelona |
And 13 more authors.
AIDS | Year: 2015
Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs. © Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved.